glp-1 clinical trials sign up A new trial supported by the National Institutes of Health (NIH) found that a medication commonly used for weight loss, such as semaglutide, may also help reduce heavy drinking in individuals glp 1 clinical trials sign

Eating enough protein and doing resistance training protects muscle as we age

Bhattarai M, Salih M, Regmi M et al (2022) Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis

This decline contributes to many age-related changes like decreased muscle mass, increased body fat, reduced bone density, and lower energy levels

First, nausea was the most commonly reported GI adverse event across all dose groups but showed a non-monotonic dose-response pattern, peaking at the 12 mg dose (35.9%) rather than the highest dose

Ann Otol Rhinol Laryngol 1987